Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Restores Vision and Retinal Health in AMD Using FDA Surrogate Endpoints
Details : Telomir-1 to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provide robust cellular protection against copper toxicity.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : The Bayshore Trust
Deal Size : $3.0 million
Deal Type : Financing
Telomir Raises $3M Straight Equity to Advance Rare Disease IND With No Warrants
Details : The financing aims to advance the clinical development of theTelomir-1, which is being evaluated for the treatment of type 2 diabetes.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : The Bayshore Trust
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : Telomir-1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Shows Strong Anti-Cancer Effects in Prostate Cancer Model
Details : Telomir-1 is the first novel small molecule, which suppresses cancer growth rather than promoting it and protects against chemotherapy-induced toxicity and mortality.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Reverses Calcium Dysregulation, Key Aging Driver, in Human Cell Study
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Pharmaceuticals Reduces Oxidative Stress, Advancing AMD Treatment
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Reverses Oxidative Stress, Explored for Avian Flu, Other Viruses
Details : Telomir-1 to fully reverse copper-induced elevation of reactive oxygen species (ROS) and provide robust cellular protection against copper toxicity in viral infections, such as avian influenza.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Pharmaceuticals Confirms Lifespan Restoration in Progeria Model
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions, like progeria.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Pharmaceuticals Confirms Copper Binding Of Telomir-1 for Wilson's Disease
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Starwood Trust
Deal Size : $1.0 million
Deal Type : Financing
Telomir Pharmaceuticals Raises $1M with No-Warrant Stock Deal at 20% Premium
Details : The financing aims to advance the company's lead product Telomir-1. It is being evaluated for the treatment of osteoarthritis and Aging.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Telomir-1
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Starwood Trust
Deal Size : $1.0 million
Deal Type : Financing
Lead Product(s) : Telomir-1
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Reports Preclinical Telomir-1 Study on Age Reversal and Longevity Benefits
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Telomir-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : Telomir-1
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable